FINWIRES · TerminalLIVE
FINWIRES

$TVTX

11 stories mentioning TVTXUpdated 4d ago

Every FINWIRES story that references TVTX, newest first.

What's the latest news on TVTX?

Insider Trading

Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing

Jula Inrig, Executive Vice President, Head of Research & Development & Chief Medical Officer, on September 15, 2026, sold 44,674 shares in Travere Therapeutics (TVTX) for $2,785,021. Following the Form 4 filing with the SEC, Inrig has control over a total of 100,491 common shares of the company, with 100,491 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000190236826000008/xslF345X05/form4-09182026_010947.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing

Elizabeth E Reed, Chief Legal Officer and General Counsel, on September 15, 2026, sold 37,500 shares in Travere Therapeutics (TVTX) for $2,337,695. Following the Form 4 filing with the SEC, Reed has control over a total of 105,389 common shares of the company, with 105,389 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/xslF345X05/form4-09182026_010948.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing

Eric M Dube, Director, Chief Executive Officer, on September 15, 2026, sold 400,000 shares in Travere Therapeutics (TVTX) for $25,390,729. Following the Form 4 filing with the SEC, Dube has control over a total of 432,886 common shares of the company, with 432,886 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000176349426000007/xslF345X05/form4-09182026_010928.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing

William E. Rote, Chief Research Officer, on September 15, 2026, sold 209,048 shares in Travere Therapeutics (TVTX) for $13,135,397. Following the Form 4 filing with the SEC, Rote has control over a total of 98,197 common shares of the company, with 98,197 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000169826226000005/xslF345X05/form4-09182026_010952.xml

$TVTX
Wire

Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says

Travere Therapeutics (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw "strong interest" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.Price: $55.61, Change: $+0.45, Percent Change: +0.83%

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing

Jeffrey A Meckler, Director, on May 04, 2026, sold 8,000 shares in Travere Therapeutics (TVTX) for $360,000. Following the Form 4 filing with the SEC, Meckler has control over a total of 87,500 common shares of the company, with 87,500 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000150691626000001/xslF345X05/form4-05062026_080516.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing

Elizabeth E Reed, Chief Legal Officer and General Counsel, on May 04, 2026, sold 24,250 shares in Travere Therapeutics (TVTX) for $1,092,657. Following the Form 4 filing with the SEC, Reed has control over a total of 105,211 common shares of the company, with 105,211 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000128330326000009/xslF345X05/form4-05062026_080511.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing

Jula Inrig, Chief Medical Officer, on May 04, 2026, sold 22,485 shares in Travere Therapeutics (TVTX) for $1,015,086. Following the Form 4 filing with the SEC, Inrig has control over a total of 113,238 common shares of the company, with 113,238 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000190236826000006/xslF345X05/form4-05062026_080509.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing

Eric M Dube, Director and Chief Executive Officer, on May 04, 2026, sold 22,500 shares in Travere Therapeutics (TVTX) for $988,875. Following the Form 4 filing with the SEC, Dube has control over a total of 432,886 common shares of the company, with 432,886 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000176349426000006/xslF345X05/form4-05062026_080504.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $2,629,975, According to a Recent SEC Filing

Eric M Dube, Director, Chief Executive Officer, on April 13, 2026, sold 64,000 shares in Travere Therapeutics (TVTX) for $2,629,975. Following the Form 4 filing with the SEC, Dube has control over a total of 432,886 common shares of the company, with 432,886 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000176349426000005/xslF345X05/form4-04162026_010408.xml

$TVTX
Insider Trading

Travere Therapeutics Insider Sold Shares Worth $2,126,452, According to a Recent SEC Filing

Elizabeth E Reed, Chief Legal Officer and General Counsel, on April 13, 2026, sold 51,500 shares in Travere Therapeutics (TVTX) for $2,126,452. Following the Form 4 filing with the SEC, Reed has control over a total of 105,211 common shares of the company, with 105,211 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438533/000128330326000008/xslF345X05/form4-04162026_010431.xml

$TVTX

Track with the FINWIRES app suite

FolioX
FolioX
Track TVTX in your portfolio
WheelAI
WheelAI
Analyze TVTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TVTX